Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.89B
EBITDA Margin
-76.84%
TTM Avg
-120.93%
3Y Avg
-91.54%
5Y Avg
-268.52%
Market Cap
$1.89B
EBITDA Margin
3.75%
TTM Avg
2.81%
3Y Avg
-0.66%
5Y Avg
-2.07%
Market Cap
$1.89B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
Market Cap
$1.84B
EBITDA Margin
-157.11%
TTM Avg
-157.28%
3Y Avg
-157.28%
5Y Avg
-157.28%
Market Cap
$1.85B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$1.92B
EBITDA Margin
-13.52%
TTM Avg
-19.53%
3Y Avg
-24.36%
5Y Avg
-23.78%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | N/A | N/A | N/A | N/A |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -76.84% | -120.93% | -91.54% | -268.52% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| Novavax, Inc. (NVAX)vs › | $1.86B | 52.59% | 11.61% | -27.43% | -466.07% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | -157.11% | -157.28% | -157.28% | -157.28% |
| Immunome, Inc. (IMNM)vs › | $1.85B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 3.91% | 4.83% | 6.92% | 8.21% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | -13.52% | -19.53% | -24.36% | -23.78% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | -27.90% | -7.22% | -21.35% | -40.43% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
